Literature DB >> 17982473

Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands.

A Poso1, J W Huffman.   

Abstract

Recent developments indicate that CB2 receptor ligands have the potential to become therapeutically important. To explore this potential, it is necessary to develop compounds with high affinity for the CB2 receptor and little affinity for the CB1 receptor. This review will discuss structure-activity relations at both receptors for classical cannabinoids and cannabimimetic indoles. Examples of CB2 selective ligands from both classes of compounds are presented and the structural features leading to selectivity are described. Two approaches, receptor mutations and molecular modelling, have been employed to investigate the interaction of ligands with both cannabinoid receptors. These results obtained from these techniques are discussed.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17982473      PMCID： PMC2219524          DOI： 10.1038/sj.bjp.0707567

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  60 in total

1.  Chemical modification of the naphthoyl 3-position of JWH-015: in search of a fluorescent probe to the cannabinoid CB2 receptor.

Authors:  Andrew S Yates; Stephen W Doughty; David A Kendall; Barrie Kellam
Journal:  Bioorg Med Chem Lett       Date:  2005-08-15       Impact factor: 2.823

2.  Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study.

Authors:  Cristina Montero; Nuria Eugenia Campillo; Pilar Goya; Juan Antonio Páez
Journal:  Eur J Med Chem       Date:  2005-01       Impact factor: 6.514

3.  Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A.

Authors:  D Shire; B Calandra; M Delpech; X Dumont; M Kaghad; G Le Fur; D Caput; P Ferrara
Journal:  J Biol Chem       Date:  1996-03-22       Impact factor: 5.157

4.  Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor.

Authors:  J W Huffman; S Yu; V Showalter; M E Abood; J L Wiley; D R Compton; B R Martin; R D Bramblett; P H Reggio
Journal:  J Med Chem       Date:  1996-09-27       Impact factor: 7.446

5.  Development and validation of a genetic algorithm for flexible docking.

Authors:  G Jones; P Willett; R C Glen; A R Leach; R Taylor
Journal:  J Mol Biol       Date:  1997-04-04       Impact factor: 5.469

6.  Adamantyl cannabinoids: a novel class of cannabinergic ligands.

Authors:  Dai Lu; Zhaoxing Meng; Ganesh A Thakur; Pusheng Fan; John Steed; Cindy L Tartal; Dow P Hurst; Patricia H Reggio; Jeffrey R Deschamps; Damon A Parrish; Clifford George; Torbjörn U C Järbe; Richard J Lamb; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2005-07-14       Impact factor: 7.446

7.  Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template.

Authors:  Rundong Zhang; Dow P Hurst; Judy Barnett-Norris; Patricia H Reggio; Zhao-Hui Song
Journal:  Mol Pharmacol       Date:  2005-04-19       Impact factor: 4.436

8.  Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists.

Authors:  John W Huffman; Gulay Zengin; Ming-Jung Wu; Jianzhong Lu; George Hynd; Kristen Bushell; Alicia L S Thompson; Simon Bushell; Cindy Tartal; Dow P Hurst; Patricia H Reggio; Dana E Selley; Michael P Cassidy; Jenny L Wiley; Billy R Martin
Journal:  Bioorg Med Chem       Date:  2005-01-03       Impact factor: 3.641

Review 9.  Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands.

Authors:  K H Raitio; O M H Salo; T Nevalainen; A Poso; T Järvinen
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

Review 10.  CB2 receptor ligands.

Authors:  J W Huffman
Journal:  Mini Rev Med Chem       Date:  2005-07       Impact factor: 3.862
View more
  25 in total

1.  Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats.

Authors:  Torbjörn U C Järbe; Hongfen Deng; Subramanian K Vadivel; Alexandros Makriyannis
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

Review 2.  Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.

Authors:  Christopher D Rosenbaum; Stephanie P Carreiro; Kavita M Babu
Journal:  J Med Toxicol       Date:  2012-03

3.  hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.

Authors:  Richard W Mercier; Ying Pei; Lakshmipathi Pandarinathan; David R Janero; Jing Zhang; Alexandros Makriyannis
Journal:  Chem Biol       Date:  2010-10-29

4.  New ursane triterpenoids from Ficus pandurata and their binding affinity for human cannabinoid and opioid receptors.

Authors:  Amgad I M Khedr; Sabrin R M Ibrahim; Gamal A Mohamed; Hany E A Ahmed; Amany S Ahmad; Mahmoud A Ramadan; Atef E Abd El-Baky; Koji Yamada; Samir A Ross
Journal:  Arch Pharm Res       Date:  2016-06-27       Impact factor: 4.946

5.  CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency.

Authors:  Reem Smoum; Saja Baraghithy; Mukesh Chourasia; Aviva Breuer; Naama Mussai; Malka Attar-Namdar; Natalya M Kogan; Bitya Raphael; Daniele Bolognini; Maria G Cascio; Pietro Marini; Roger G Pertwee; Avital Shurki; Raphael Mechoulam; Itai Bab
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

6.  Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation.

Authors:  Dennis W Szymanski; Malvina Papanastasiou; Katja Melchior; Nikolai Zvonok; Richard W Mercier; David R Janero; Ganesh A Thakur; Sangwon Cha; Billy Wu; Barry Karger; Alexandros Makriyannis
Journal:  J Proteome Res       Date:  2011-09-13       Impact factor: 4.466

7.  Modeling of ligand binding to G protein coupled receptors: cannabinoid CB1, CB2 and adrenergic β 2 AR.

Authors:  Dorota Latek; Michal Kolinski; Umesh Ghoshdastider; Aleksander Debinski; Rafal Bombolewski; Anita Plazinska; Krzysztof Jozwiak; Slawomir Filipek
Journal:  J Mol Model       Date:  2011-03-02       Impact factor: 1.810

8.  Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors.

Authors:  Peng Yang; Kyaw-Zeyar Myint; Qin Tong; Rentian Feng; Haiping Cao; Abdulrahman A Almehizia; Mohammed Hamed Alqarni; Lirong Wang; Patrick Bartlow; Yingdai Gao; Jürg Gertsch; Jumpei Teramachi; Noriyoshi Kurihara; Garson David Roodman; Tao Cheng; Xiang-Qun Xie
Journal:  J Med Chem       Date:  2012-10-31       Impact factor: 7.446

9.  Difference and Influence of Inactive and Active States of Cannabinoid Receptor Subtype CB2: From Conformation to Drug Discovery.

Authors:  Jianping Hu; Zhiwei Feng; Shifan Ma; Yu Zhang; Qin Tong; Mohammed Hamed Alqarni; Xiaojun Gou; Xiang-Qun Xie
Journal:  J Chem Inf Model       Date:  2016-05-26       Impact factor: 4.956

10.  2,3-Dihydro-1-benzofuran derivatives as a series of potent selective cannabinoid receptor 2 agonists: design, synthesis, and binding mode prediction through ligand-steered modeling.

Authors:  Philippe Diaz; Sharangdhar S Phatak; Jijun Xu; Frank R Fronczek; Fanny Astruc-Diaz; Charles M Thompson; Claudio N Cavasotto; Mohamed Naguib
Journal:  ChemMedChem       Date:  2009-10       Impact factor: 3.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.